Pathogen inactivation in labile blood products transfusion safety and economic impact - Discussion

被引：0
|
作者：
Bourel, Michel
Caen, Jacques
Dirreimer, Guy
Vacheron, Andre
Sansonetti, Philippe
Michel-Briand, Yvon
机构：
来源：
BULLETIN DE L ACADEMIE NATIONALE DE MEDECINE | 2006年 / 190卷 / 01期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：186 / 188
页数：3
相关论文
共 50 条
  • [31] IMPACT OF A BLOOD SAFETY ACT ON AUTOLOGOUS BLOOD-TRANSFUSION
    GLACKIN, K
    COOPER, P
    TRANSFUSION, 1994, 34 (10) : S84 - S84
  • [32] Pathogen inactivation in cellular blood components: Clinical trials and implications of introduction to transfusion medicine
    AuBuchon, JP
    VOX SANGUINIS, 2002, 83 : 271 - 275
  • [33] Transfusion of labile blood products: How to inform patients serenely without scaring them?
    Villevieille, Thierry
    Fevre, Guillaume
    Sfez, Michel
    Raucoules-Aime, Marc
    Cabaud, Jean-Jacques
    ANESTHESIE & REANIMATION, 2020, 6 (04): : 353 - 355
  • [34] Impact of platelet pathogen inactivation on blood component utilization and patient safety in a large Austrian Regional Medical Centre
    Amato, M.
    Schennach, H.
    Astl, M.
    Chen, C. Y.
    Lin, J. -S.
    Benjamin, R. J.
    Nussbaumer, W.
    VOX SANGUINIS, 2017, 112 (01) : 47 - 55
  • [35] Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both?
    Jacquot, Cyril
    Delaney, Meghan
    TRANSFUSION, 2018, 58 (09) : 2095 - 2101
  • [36] Specific aspects of blood products safety in hemostasis and transfusion medicine
    Seyfert, UT
    Mörsdorf, S
    Mertzlufft, F
    ANASTHESIOLOGIE INTENSIVMEDIZIN NOTFALLMEDIZIN SCHMERZTHERAPIE, 1999, 34 (08): : 488 - 492
  • [37] Remuneration of blood donors and its impact on transfusion safety
    Offergeld, R
    Burger, R
    VOX SANGUINIS, 2003, 85 (01) : 49 - 49
  • [38] Safety of Blood Products What are the Risks of new Infection Diseases for Blood Transfusion?
    Ruchalla, Elke
    TRANSFUSIONSMEDIZIN, 2016, 6 (04) : 161 - 161
  • [39] Meeting the challenges of blood safety in the 21st century: Pathogen inactivation
    Osselaer, JC
    TRANSFUSION MEDICINE AND HEMOTHERAPY, 2004, 31 : 1 - 1
  • [40] Current prescription practices for labile blood products in France: An investigation by the french society of transfusion (SFTS).
    Rieux, C
    Bastuji-Garin, S
    Vicariot, M
    Waller, C
    Quaranta, JF
    Bierling, P
    Reyes, F
    BLOOD, 1999, 94 (10) : 121B - 121B
12345